No registrations found.
ID
Source
Brief title
Health condition
Irritable Bowel Syndrome (IBS) = Prikkelbare Darm Syndroom (PDS).
probiotics = probiotica
cytokine profiles = cytokine profielen
visceroperception = visceroperceptie
lowgrade inflammation = laaggradige ontsteking
Sponsors and support
1-19, 1 Chome, Higashi-Shinbashi
Minato-ku 105-8660
Tokyo JAPAN
Contact person: Mr Oosawa
Contact person in Europe: Dr S Kudo or Dr J Zhao, science manager
Science department of Yakult Europe B.V.
Yakult Europe B.V.
Schutsluisweg 1
1332 EN ALMERE
The Netherlands
0031(0)365211300
Intervention
Outcome measures
Primary outcome
To assess the effect of the probiotic product "Yakult" on symptoms in patients with IBS.
Secondary outcome
Secondary objective:
* To assess the effect of the probiotic product "Yakult" on quality of life in patients with IBS.
Exploratory objectives:
* To investigate the influence of the probiotic product on the intestinal flora composition of the IBS patients.
* To characterize the intestinal flora of the IBS patients by comparison to that of the healthy volunteers.
* To assess the effect of a 8 week treatment with the probiotic product on cytokine profiles in IBS patients.
* To assess the difference in visceroperception before and after treatment in the intervention group vs placebo group
* To assess the presence of low grade inflammation in sigmoid biopsies in IBS patients before and after treatment with probiotic or placebo
Background summary
N/A
Study objective
Treatment with a probiotic dairy product releives symptoms in Irritable Bowel Syndrome patients. It also improves quality of life of the patients, and has an positive effect on the composition of the microbiota. Cytokine stimulation profiles will differ before and after treatment with the probiotic product, and genetic cytokine profiles are different in (subtypes) of IBS patients compared to healthy controls.
Hypersensitivity of the rectum will be less after intervention with the probiotic product.
Lowgrade inflammation will be less after intervention with the probiotic product, all the above compared to placebo treatment.
Study design
01-03-07 start inclusion period
01-06-08 end inclusion period
01-10-08 end follow-up period
01-05-09 end analysis period
Intervention
* Run in visit (week -6): inclusion following inclusion criteria, informed consent
* Start intervention visit (week 0): fecal analysis, start probiotics/placebo, collection of blood sample, barostat measurement, sigmoscopy for collecting 4 biopsies
* Intervention period visit (week 4): check of protocol with patient
* Intervention period visit (week 8): fecal analysis, collection of blood sample, barostat measurement, sigmoscopy for collecting 4 biopsies, after that stop probiotics/placebo
* Phone consultation (week 12): check of protocol with patient
* Follow-up visit (week 16): fecal analysis, end of study period
Houtlaan 55
Annemieke Y. Thijssen
Leiden 2334 CK
The Netherlands
0031(0)71-5178178, pager 203
aythijssen@diaconessenhuis.nl
Houtlaan 55
Annemieke Y. Thijssen
Leiden 2334 CK
The Netherlands
0031(0)71-5178178, pager 203
aythijssen@diaconessenhuis.nl
Inclusion criteria
Patients will be included when:
1. Diagnosed with IBS according to the ROME II criteria.
2. Age between 18 and 65 years.
3. Giving informed consent
4. Minimum mean symptom score > 2 (scale 0-20 for the 5 symptoms: discomfort, pain, constipation, diarrhea and bloating) during pre run-in.
Exclusion criteria
1. Patients who have had gastrointestinal surgery resulting in gastric resection, small intestinal or colonic resection.
2. Patients who are allergic to milk protein
3. Patients who have a high intake of yogurt (over 500 ml per day)
4. Patients where LcS was detected before the start of sample ingestion in the fecal samples.
5. Patients not able to stop medication that influences stool frequency (laxatives or antidiarrhoeals)
6. Patients who are vegetarians.
7. Patients who have used probiotics in a period of four weeks prior to the start of the study.
8. Patients who have received antibiotics/antibacterials in a period of four weeks before the start of the study and during the intervention.
9. Patients who did not commit to drinking the minimum dosage of the samples
10. Patients whose submission of fecal samples was done after stopping drinking samples and
11. Patients who submitted fecal samples more than two days earlier than the end of the drinking period
12. Patients with any relevant neurological, cardiovascular, pulmonary, metabolic, haematological or endocrinic disorder that is not stabilised.
13. Patients who have participated in a clinical study with an unregistered (clinical trial) product within four weeks before the start of the study.
14. Patients with a history of drug or alcohol abuse.
15. Any medical condition which the investigator considers sufficiently serious to interfere with the conduct of the trial or that constitutes any risk to the patients.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL1190 |
| NTR-old | NTR1235 |
| Other | MEC : P05.131 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |